ES2155070T3 - Conjugados peptido-carbohidrato que generan inmunidad por las celulas t. - Google Patents

Conjugados peptido-carbohidrato que generan inmunidad por las celulas t.

Info

Publication number
ES2155070T3
ES2155070T3 ES93912042T ES93912042T ES2155070T3 ES 2155070 T3 ES2155070 T3 ES 2155070T3 ES 93912042 T ES93912042 T ES 93912042T ES 93912042 T ES93912042 T ES 93912042T ES 2155070 T3 ES2155070 T3 ES 2155070T3
Authority
ES
Spain
Prior art keywords
carbohydrate
peptide
cells
immunogenic
carbohydrate conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93912042T
Other languages
English (en)
Inventor
Mikael Jondal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9201338A external-priority patent/SE9201338D0/xx
Priority claimed from SE9202553A external-priority patent/SE9202553D0/xx
Priority claimed from SE9203897A external-priority patent/SE9203897D0/xx
Priority claimed from SE9301141A external-priority patent/SE9301141D0/xx
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2155070T3 publication Critical patent/ES2155070T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

LA INVENCION SE REFIERE A UNA NUEVA CLASE DE COMPUESTOS BIOLOGICAMENTE ACTIVOS, A PROCESOS PARA SU PRODUCCION Y A SU USO EN LA TERAPIA. MAS PARTICULARMENTE LA INVENCION SUMINISTRA CONJUGADOS INMUNOGENICOS UTILES PARA GENERAR LA INMUNIDAD DE LAS CELULAS T CONTRA LAS ESTRUCTURAS DE CARBOHIDRATO ASOCIADAS CON LOS TUMORES O CONTRA LAS ESTRUCTURAS DE CARBOHIDRATOS EXPRESADAS EN AGENTES INFECCIOSOS Y/O CELULAS ANFITRIONAS INFECTADAS. EL MENCIONADO CONJUGADO INMUNOGENICO COMPRENDE I) UN COMPONENTE PEPTIDO CAPAZ DE UNIR UNA MOLECULA MHC DE CLASE I; Y II) UN COMPONENTE DE CARBOHIDRATO QUE TIENE LA ESPECIFICIDAD INMUNOGENICA PARA DICHA ESTRUCTURA DE CARBOHIDRATO.
ES93912042T 1992-04-28 1993-04-23 Conjugados peptido-carbohidrato que generan inmunidad por las celulas t. Expired - Lifetime ES2155070T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9201338A SE9201338D0 (sv) 1992-04-28 1992-04-28 New active compounds
SE9202553A SE9202553D0 (sv) 1992-09-07 1992-09-07 New active compounds ii
SE9203897A SE9203897D0 (sv) 1992-12-23 1992-12-23 New active compounds iii
SE9301141A SE9301141D0 (sv) 1993-04-06 1993-04-06 New active compounds iv

Publications (1)

Publication Number Publication Date
ES2155070T3 true ES2155070T3 (es) 2001-05-01

Family

ID=27484749

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93912042T Expired - Lifetime ES2155070T3 (es) 1992-04-28 1993-04-23 Conjugados peptido-carbohidrato que generan inmunidad por las celulas t.

Country Status (19)

Country Link
US (2) US5807559A (es)
EP (1) EP0675733B1 (es)
JP (1) JPH07506358A (es)
CN (1) CN1096032A (es)
AT (1) ATE197903T1 (es)
AU (1) AU676679B2 (es)
CA (1) CA2134097A1 (es)
DE (1) DE69329735T2 (es)
DK (1) DK0675733T3 (es)
ES (1) ES2155070T3 (es)
GR (1) GR3035501T3 (es)
IL (1) IL105503A (es)
IS (1) IS4010A (es)
MA (1) MA22885A1 (es)
MY (1) MY108864A (es)
PT (1) PT675733E (es)
SI (1) SI9300223A (es)
TN (1) TNSN93045A1 (es)
WO (1) WO1993021948A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083929A (en) * 1991-05-06 2000-07-04 The Biomembrane Institute Extended type 1 chain glycosphingolipids as tumor-associated antigens
DE4436164A1 (de) * 1994-10-10 1996-04-11 Hoechst Ag Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US6841543B1 (en) 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
WO1998015286A1 (en) * 1996-10-08 1998-04-16 La Jolla Institute For Allergy & Immunology Carbohydrate-specific cytolytic t cells
ES2265162T3 (es) * 1997-03-27 2007-02-01 Institut Pasteur Carbohidrato glucopeptido de antigeno multiple, vacuna que comprende el mismo y su utilizacion.
US20070237785A1 (en) * 1997-03-27 2007-10-11 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
JP4308918B2 (ja) 1997-04-16 2009-08-05 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ （２，６）−ＳＴエピトープクラスターを有するα−Ｏ−結合複合糖質、その製造方法および使用
US7550146B2 (en) * 1997-04-16 2009-06-23 Sloan-Kettering Institute For Cancer Research Glycopeptide conjugates and uses thereof
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
CA2324616A1 (en) * 1998-03-25 1999-09-30 Sloan-Kettering Institute For Cancer Research Trimeric antigenic o-linked glycopeptide conjugates, methods of preparation and uses thereof
US7402307B2 (en) * 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
WO1999050392A1 (en) 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
EP1073667A2 (en) * 1998-04-28 2001-02-07 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US20030091546A1 (en) * 1998-11-12 2003-05-15 Barber Jack R. Methods of suppressing immune response by gene therapy
US7824687B2 (en) 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
JP5111705B2 (ja) * 1999-08-20 2013-01-09 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ 新規な複合多糖、グリコアミノ酸、これらへの中間体、及びこれらの使用
US7854934B2 (en) * 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
WO2004069873A2 (en) * 2003-02-06 2004-08-19 Tripep Ab Antigen/antibody or ligand/receptor glycosylated specificity exchangers
EP1720567A2 (en) * 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma
US20060263415A1 (en) 2005-05-05 2006-11-23 Sensient Flavors Inc. Production of beta-glucans and mannans
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
JP2013527753A (ja) 2010-03-23 2013-07-04 イントレキソン コーポレーション 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用
EP2500033A1 (en) 2011-03-17 2012-09-19 Institut Pasteur Method for preparing muliple antigen glycopeptide carbohydrate conjugates
KR102081868B1 (ko) 2011-06-28 2020-02-26 이노비오 파마수티컬즈, 인크. 최소 침습 피부 전기천공 장치
EP2606897A1 (en) * 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Methods and compositions for the treatment of diseases caused by enveloped viruses
EP3651795A4 (en) * 2017-07-12 2021-05-26 The Board of Trustees of the Leland Stanford Junior University COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH AN H3K27M MUTATION

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2004744B (en) * 1977-09-28 1982-05-26 Sanderson A R Immonulogical preparations
CA1335883C (en) * 1986-07-08 1995-06-13 Bryan Michael Longenecker Enhancement of the cellular immune response
JP2921574B2 (ja) * 1988-02-01 1999-07-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンの担体分子としてのｔ細胞のエピトープ
EP0400077A4 (en) * 1988-02-12 1990-12-27 The Regents Of The University Of California Use of synthetic peptides to generate and manipulate cellular immunity
US5229289A (en) * 1988-03-11 1993-07-20 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
CA1337403C (en) * 1988-03-28 1995-10-24 Biomembrane Institute (The) Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones
WO1991001146A1 (en) * 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
CA2067124A1 (en) * 1989-08-28 1991-03-01 Patricia L. Domen Cationized carriers for immunogen production
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.

Also Published As

Publication number Publication date
DE69329735D1 (de) 2001-01-11
IS4010A (is) 1993-10-29
MY108864A (en) 1996-11-30
GR3035501T3 (en) 2001-06-29
US6033669A (en) 2000-03-07
DK0675733T3 (da) 2001-05-07
AU4274693A (en) 1993-11-29
ATE197903T1 (de) 2000-12-15
CN1096032A (zh) 1994-12-07
IL105503A (en) 1999-05-09
DE69329735T2 (de) 2001-08-02
TNSN93045A1 (fr) 1994-03-17
EP0675733A1 (en) 1995-10-11
WO1993021948A1 (en) 1993-11-11
MA22885A1 (fr) 1993-12-31
CA2134097A1 (en) 1993-11-11
US5807559A (en) 1998-09-15
IL105503A0 (en) 1993-08-18
EP0675733B1 (en) 2000-12-06
PT675733E (pt) 2001-05-31
SI9300223A (en) 1994-03-31
AU676679B2 (en) 1997-03-20
JPH07506358A (ja) 1995-07-13

Similar Documents

Publication Publication Date Title
ES2155070T3 (es) Conjugados peptido-carbohidrato que generan inmunidad por las celulas t.
DK1036058T3 (da) Adamantanderivater
DK1036059T3 (da) Adamantanderivater
BR9303469A (pt) Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas
ES2140076T3 (es) Vacunas que contienen una saponina y un esterol.
ES2045470T3 (es) Formulaciones medicinales en aerosol.
EA199800946A1 (ru) Концентрированный препарат антител
ATE321131T1 (de) Mutierte klasse-i-mhc-moleküle
MX9203439A (es) Una citocina mamifera, il-11
ATE88898T1 (de) Cd4-polypeptidderivate.
UA26056C2 (uk) Пристрій для еhергетичhої активації хребта
IT1248475B (it) Composti di inclusione di nimesulide con ciclodestrine
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
DE59010462D1 (de) Neue Cobalamin-Säurehydrazide und davon abgeleitete Cobalamin-Konjugate
JO1766B1 (en) Effective new compounds
TW332816B (en) Peptide and carbohydrate
FI961339A0 (fi) Triaryylieteenijohdannaiset käytettäväksi hoidossa
IT8820245A0 (it) Palmitoil_fruttosio_1,6_difosfato, suo uso terapeutico e relativi metodi di preparazione.
TH13666A (th) สารประกอบออกฤทธิ์ชนิดใหม่
IT1257479B (it) Derivati prostaglandinici aventi effetti radioprotettivi
IT1229566B (it) Gel di antracicline e loro uso terapeutico.
NO884941L (no) Konjugat av metallothionein eller et metallothioneinfragment og et maalsoekende biologisk aktivt molekyl, som er anvendelig som mellomprodukt ved fremstilling av lignende merkede konjugater.
ITVI950066A0 (it) Procedimento per la fabbricazione di pannelli per l'impiego nel setto-re del mobile, a basso costo e atossico

Legal Events

Date Code Title Description
FA2A Application withdrawn

Effective date: 19950313

FG2A Definitive protection

Ref document number: 675733

Country of ref document: ES